SCHEMBL1114450

SCHEMBL1114450

COc1ccccc1N1CCN(CCCCOc2ccc(CCn3ncnn3)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.63
ALDH1A1 P00352 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
MAPT P10636 1/20 0.63
NLRP1 Q9C000 1/20 0.63
SLC6A2 P23975 1/20 0.59
SLC6A4 P31645 1/20 0.59
DRD2 P14416 5/20 0.58
DRD3 P35462 5/20 0.58
DRD1 P21728 2/20 0.58
DRD4 P21917 2/20 0.58
HTR2A P28223 2/20 0.58
ADRA1A P35348 1/20 0.58
HTR1A P08908 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1114437 0.92 LMNA (0.64) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114668 0.89 LMNA (0.67) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114391 0.84 LMNA (0.62) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114558 0.84 HTR1A (0.66) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114603 0.83 LMNA (0.63) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114925 0.83 LMNA (0.63) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114351 0.83 LMNA (0.63) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
Hydrochloric Acid SCHEMBL1114520 0.83 HTR1A (0.65) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114851 0.83 DRD2 (0.53) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL1114854 0.82 LMNA (0.69) LMNAALDH1A1SMN1; SMN2MAPTNLRP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP claimed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US claimed
US-7985752-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK HOLDINGS CO., LTD. (KR) 2011-07-26 US claimed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US claimed
EP-2279179-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK Holdings Co., Ltd. (KR) 2011-02-02 EP claimed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US claimed
WO-2009145591-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2009-12-03 WO claimed
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP disclosed
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-7985752-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK HOLDINGS CO., LTD. (KR) 2011-07-26 US disclosed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US disclosed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US disclosed
EP-2279179-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK Holdings Co., Ltd. (KR) 2011-02-02 EP disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
WO-2009145591-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF HTR5A, HTR1A, HTR2A LMNA 2733/4885ALDH1A1 495/4885SMN1; SMN2 2583/4885
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF HTR5A, HTR1A, HTR2A LMNA 2590/4885ALDH1A1 523/4885SMN1; SMN2 2545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.